KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Operating Margin: 2017-2024

Historic Operating Margin for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -3,052.68%.

  • Aquestive Therapeutics' Operating Margin fell 2841.00% to -89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 45990.00%. This contributed to the annual value of -3,052.68% for FY2024, which is 302282.00% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Operating Margin stood at -3,052.68% for FY2024, which was down 10,124.71% from -29.86% recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Operating Margin registered a high of -29.86% during FY2023, and its lowest value of -3,052.68% during FY2024.
  • For the 3-year period, Aquestive Therapeutics' Operating Margin averaged around -1,056.92%, with its median value being -88.23% (2022).
  • In the last 5 years, Aquestive Therapeutics' Operating Margin surged by 100,410bps in 2021 and then plummeted by 302,282bps in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Operating Margin stood at -1,072.33% in 2020, then spiked by 100,410bps to -68.22% in 2021, then plummeted by 2,000bps to -88.23% in 2022, then skyrocketed by 5,837bps to -29.86% in 2023, then plummeted by 302,282bps to -3,052.68% in 2024.